Thoraxonkologische Studien
ABP 2019
Titel: Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK*NSCLC) patients by deep phenotyping
Indikation: ALK, NSCLC
Patienteneinschluss: Rekrutierung beendet
EudraCT-Nummer: 2019-001828-36
ANTELOPE
Titel: Atezolizumab/Carboplatin/nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in metastatic TTF1 negative lung adenocarcinoma
Indikation: NSCLC
Patienteneinschluss: rekrutierend
EudraCT-Nummer: 2023-505054-17-00
AVANZAR
Titel: A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Indikation: NSCLC
Patienteneinschluss: rekrutierend
EudraCT-Nummer: 2021-004606-21
Weitere Informationen zur Studie auf www.clinicaltrialsregister.eu
BMS CA 209-73L
Titel: Nivolumab + Chemoradiotherapie (CCRT) gefolgt von Nivolumab und Ipilimumab oder Nivolumab + CCRT gefolgt von Nivolumab alleine vs. CCRT gefolgt von Durvalumab bei Patienten mit unbehandeltem, inoperablem und lokal fortgeschrittenem NSCLC
Indikation: NSCLC
Patienteneinschluss: Rekrutierung beendet
EudraCT-Nummer: 2019-001222-98
Weitere Informationen zur Studie auf www.clinicaltrials.gov
BMS CA 209 9 LA
Titel: A Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)
Indikation: NSCLC
Patienteneinschluss: Rekrutierung beendet
EudraCT-Nummer: 2017-001195-35
Weitere Informationen zur Studie auf www.clinicaltrials.gov
BO 42592
Titel: A phase II, randomized, double-blind, placebo-controlled study of Tiragolumab in combination with Atezolizumab plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab plus Pemetrexed and Carboplatin/Cisplatin in patients with previously untreated advanced non-squamous NSCLC
Indikation: NSCLC
Patienteneinschluss: Rekrutierung beendet
EudraCT-Nummer: 2020-002851-39
Weitere Informationen zur Studie auf www.clinicaltrials.gov
BO 42777
Titel: A PHASE I-III, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS, WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE III NON-SMALL CELL LUNG CANCER
Indikation: NSCLC
Patienteneinschluss: rekrutierend
EudraCT-Nummer: 2021-004149-19
Weitere Informationen zur Studie auf www.clinicaltrialsregister.eu
BO 42863
Titel: A Phase 1/2 Study of the Highly-selective REF Inhibitor, Blue 667, in patients with Thyroid Cancer, NSCLC and other advanced solid tumors
Indikation: Thyroid Cancer, NSCLC, other advanced solid tumors
Patienteneinschluss: Rekrutierung beendet
EudraCT-Nummer: 2016-004390-41
Weitere Informationen zur Studie auf www.clinicaltrials.gov
BO45217
Titel: A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB VERSUS SOTORASIB OR ADAGRASIB IN PATIENTS WITH PREVIOUSLY TREATED KRAS G12C-POSITIVE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Indikation: NSCLC
Patienteneinschluss: rekrutierend
EudraCT-Nummer: 2024-510908-37-00
Weitere Informationen zur Studie auf clinicaltrials.gov
CANOPY- A
Titel: A phase III, multicenter, randomized, double blind, placebocontrolled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)
Indikation: NSCLC
Patienteneinschluss: Rekrutierung beendet
EudraCT-Nummer: 2017-004011-39
Weitere Informationen zur Studie auf www.clinicaltrials.gov
CINC280I12201
Titel: A randomized, open label, multicenter phase II study evaluating the efficacy and safety of capmatinib (INC280) plus pembrolizumab versus pembrolizumab alone as first line treatment for locally advanced or metastatic non-small cell lung cancer with PD-L1 ≥ 50%
Indikation: NSCLC
Patienteneinschluss: Rekrutierung beendet
EudraCT-Nummer: 2019-002660-27
Destiny Lung 04
Titel: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations
Indikation: NSCLC
Patienteneinschluss: Rekrutierung beendet
EudraCT-Nummer: 2021-000634-33
Weitere Informationen zur Studie auf www.clinicaltrials.gov
eVOLVE-Lung 02
Titel: A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC).
Indikation: NSCLC
Patienteneinschluss: rekrutierend
EudraCT-Nummer: 2023-000056-38
Weitere Informationen zur Studie auf clinicaltrials.gov
eVOLVE Meso
Titel: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural Mesothelioma
Indikation: Mesotheliom
Patienteneinschluss: rekrutierend
EU-CT Nummer: 2023-000067-32
Weitere Informationen zur Studie auf clinicaltrials.gov
GO41767
Titel: A phase III, randomized, double-blind, placebo-controlled Study of ATEZOLIZUMAB plus CARBOPLATIN and ETOPOSIDE with or without TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) in patients with untreated extensive-stage small cell lung cancer
Indikation: small cell lung cancer
Patienteneinschluss: Rekrutierung beendet
EudraCT-Nummer: 2019-003301-97
Weitere Informationen zur Studie auf www.clinicaltrials.gov
GO 43104 (SCLC)
Titel: A phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab as maintenance therapy in participants with extensive-stage small-cell lung cancer (ES-SCLC) following first-line induction therapy with carboplatin,etoposide and atezolizumab
Indikation: ES-SCLC
Patienteneinschluss: Rekrutierung beendet
EudraCT-Nummer: 2021-001930-20
Molecular Fingerprinting in Cancer Detection L4L
Titel: Molekulares Fingerprinting zur Krebserkennung: Evaluation feldaufgelöster Spektroskopie zur in-Vitro Diagnostik verschiedener Krebsentitäten
Indikation: NSCLC, COPD
Patienteneinschluss: rekrutierend
EudraCT-Nummer: n.a.
Mariposa 73841937NSC3003
Titel: A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus singe Agent Osimertinib versus Lazertinib als First-Line Treatment in patients with EGFR-Mutated locally Advance ord Metastatic Non-Small Cell Lung Cancer
Indikation: NSCLC
Patienteneinschluss: Rekrutierung beendet
EudraCT-Nummer: 2020-000743-31
Weitere Informationen zur Studie auf www.clinicaltrials.gov
MK 7684-A-002
Titel: A Phase II, multicenter, randomized study to compare the Eficacy and safety of MK-7684A or MK-7694A plus Docetaxel versus Docetaxel Monotherapy in the treatment of patients with metastatic NSCLC with progressive disease after treatment with a platin doublet chemotherapy and Immunotherapy
Indikation: NSCLC
Patienteneinschluss: Rekrutierung beendet
EudraCT-Nummer: 2020-004034-38
Weitere Informationen zur Studie auf www.clinicaltrials.gov
MK3475-598
Titel: A Phase III, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs
Pembrolizumab plus Placebo in Previously Untreated, Metastatic/Recurrent Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive (TPS > or = 50%)
Indikation: NSCLC
Patienteneinschluss: Rekrutierung beendet
EudraCT-Nummer: 2016-004364-20
Weitere Informationen zur Studie auf www.clinicaltrials.gov
MK 3475-587
Titel: A Multicenter, Open-label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial
Indikation: NSCLC
Patienteneinschluss: aktiv
EudraCT-Nummer: 2017-004417-42
Weitere Informationen zur Studie auf www.clinicaltrials.gov
MK 3475-671
Titel: Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)
Indikation: NSCLC
Patienteneinschluss: Rekrutierung beendet
EudraCT-Nummer: 2017-001832-21
Weitere Informationen zur Studie auf www.clinicaltrials.gov
MK 3475-D46 (Evoke 03)
Titel: An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than or Equal to 50% Metastatic Non-small Cell Lung Cancer
Indikation: NSCLC
Patienteneinschluss: rekrutierend
EudraCT-Nummer: 2022-000836-49
Weitere Informationen zur Studie auf clinicaltrials.gov
MSD V940 /mRNA-4157
Titel: A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer(INTerpath-002)
Indikation: NSCLC
Patienteneinschluss: rekrutierend
EudraCT Nummer: 2023-504923-20
Weitere Informationen zur Studie auf clinicaltrials.gov
MO 41552
Titel: RANDOMIZED, OPEN LABEL, MULTICENTER, PHASE III STUDY OF ENTRECTINIB VERSUS CRIZOTINIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER HARBORING ROS1 GENE REARRANGEMENTS WITH AND WITHOUT CENTRAL NERVOUS SYSTEM METASTASES
Indikation: NSCLC
Patienteneinschluss: rekrutierend
EudraCT-Nummer: 2019-003859-11
Weitere Informationen zur Studie auf clinicaltrials.gov
TAK-788-3001
Titel: A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFRExon 20 Insertion Mutation
Indikation: NSCLC
Patienteneinschluss: Rekrutierung beendet
EudraCT-Nummer: 2019-001845-42
Weitere Informationen zur Studie auf www.clinicaltrials.gov
Pacific8
Titel: Phase III, Randomised, Double‑blind, Placebo‑controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non‑small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum‑based Concurrent Chemoradiation Therapy
Indikation: NSCLC
Patienteneinschluss: rekrutierend
EudraCt-Nummer: 2021-004327-32
Weitere Informationen zur Studie auf clinicaltrials.gov
SAFFRON
Titel: Phase III study in EGFR mutated, MET Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib
Indikation: NSCLC
Patienteneinschluss: rekrutierend
EudraCt-Nummer: 2021-006374-24
Weitere Informationen zur Studie auf clinicaltrials.gov
TIGER MESO
Titel: TTFields in general routine clinical care in patients with pleural mesothelioma study
Indikation: Pleural Mesotheliom
Patienteneinschluss: rekrutierend
Project No.: NCT05538806
Weitere Informationen zur Studie auf clinicaltrials.gov
Pneumologische Studien
KIN001-2003 COVID 19
Titel: An 8-week double-blind, randomized, placebocontrolled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 mg daily on COVID-19 development in hospitalized patients
Indikation: SARS-CoV-2
Patienteneinschluss: Rekrutierung beendet
EudraCT-Nummer: 2020-005849-16
KIN1902-2001 Sarkoidose
Titel: A Randomized, Double-blind, Placebo-controlled Phase 2 Study with Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects with Chronic Pulmonary Sarcoidosis
Indikation: Sarkoidose
Patienteneinschluss: rekrutierend
EudraCt-Nummer: 2021-004794-31
PneuRX-Lungenemphysem-Register-Studie
Titel: Versorgungsanalyse der Lungen Volumenteilreduktion bei Patienten mit einer schwergradigen chronischen Bronchitis mit dominantem Emphysem (COPD)
Indikation: Emphysem, COPD
Patienteneinschluss: rekrutierend
IM027068
Titel: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
Indikation: IPF
Patienteneinschluss: rekrutierend
EudraCT-Nummer: 2023-503697-21
IM0271015
Titel: A multicenter, randomized, double-blind, placebo controlled study to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with progressive pulmonary fibrosis (PPF).
Indikation: PPF
Patienteneinschluss: rekrutierend
EudraCT-Nummer: 2023-503699-25
Weitere Informationen zur Studie auf clinicaltrials.gov
Infektiologische Studien
KIN001-2003 COVID 19
Titel: An 8-week double-blind, randomized, placebocontrolled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 mg daily on COVID-19 development in hospitalized patients
Indikation: SARS-CoV-2
Patienteneinschluss: Rekrutierung beendet
EudraCT-Nummer: 2020-005849-16
Otsuka-Pass Thioridazin-Therapiestudie
Titel: A Multicentre, EU-wide, Non-Interventional Post-Authorisation Study to Assess the Safety and Usage of Delamanid in Routine Medical Practice in Multidrug-Resistant Tuberculosis Patients
Indikation: XDR-TB
Patienteneinschluss: Rekrutierung beendet
EudraCT-Nummer: 2010-022271-59
PCP-Pneumocystis
Titel: Etablierung neuer diagnostischer Verfahren zur Erkennung der Pneumocystis jirovecii Pneumonie
Indikation: Pneumocystis jirovecii Pneumonie
Patienteneinschluss: rekrutierend
RKI – virologische SARI-Surveillance (Pilotstudie)
Titel: Virologische Surveillance schwerer akuter respiratorischer Infektionen bei stationär
behandelten Patienten (SARI-Surveillance)
Indikation: akute respiratorische Erkrankung und stationäre Aufnahme
Patienteneinschluss: Rekrutierung beendet
RKI – virologische SARI-Surveillance (Multizentrische Studie)
Titel: Virologische Surveillance schwerer akuter respiratorischer Infektionen bei stationär
behandelten Patienten (SARI-Surveillance)
Indikation: akute respiratorische Erkrankung und stationäre Aufnahme
Patienteneinschluss: rekrutierend
TID-2
Titel: TID-2 Synopsis Studie: Sammlung von Blutproben für die Bewertung der analytischen Leistung von zwei neuen In-vitro-Testsystemen für die Tuberkulose- Diagnostik
Indikation: Tuberkulose
Patienteneinschluss: Rekrutierung beendet
TID 3_ RBAG-2023-01
Titel: Evaluation of the clinical performance of the enzyme-linked immunosorbent assay RIDASCREEN® TB and the immunochromatographic lateral flow assay RIDA®QUICK TB in human plasma samples
Indikation: Tuberkulose
Patienteneinschluss: Rekrutierung beendet
Project No.: 2016-0013
ERADICATE
Titel: Inhaled ColiFin® in adult bronchiectasis patients with new asymptomatic Pseudomonas aeruginosa infection an open-label, proof of concept – randomized controlled trial.
Indikation: New asymptomatic Pseudomonas aeruginosa infection
Patienteneinschluss: rekrutierend
EU-CT Nummer: 2023-509277-22-00
Stand 19.12.2024